{"entity":{"id":"paper-epcoritamab-dlbcl-drugs-2023","kind":"paper","name":"Epcoritamab: First Approval","aka":[],"tldr":"Review on Epcoritamab in Diffuse large B-cell lymphoma, in Drugs (2023), one of the most cited Europe PMC records with Epcoritamab in its title.","summary":"Epcoritamab (epcoritamab-bysp; Epkinly™; Tepkinly ®) is a subcutaneously administered CD3×CD20 T-cell-engaging bispecific antibody being co-developed by Genmab and AbbVie for the treatment of mature B-cell non-Hodgkin lymphoma subtypes (B-NHLs), including diffuse large B-cell lymphoma (DLBCL). Epcoritamab received its first (conditional) approval on 19 May 2023, in the USA, for the treatment of adult patients with relapsed or refractory (R/R) DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥ 2 lines of systemic therapy. Elsewhere, epcoritamab has received a positive opinion in the EU as a monotherapy for the treatment of adults with R/R DLBCL after ≥ 2 lines of systemic therapy, and is currently under regulatory review in Japan for the treatment of adults with R/R large B-cell lymphoma after ≥ 2 lines of systemic therapy. Clinical development of epcoritamab as monotherapy and in combination with standard of care agents for the treatment of mature B-NHLs is ongoing globally. This article summarizes the milestones in the development of epcoritamab leading to this first approval for R/R DLBCL.\n\nIndexed on Europe PMC as PubMed record 37597091 (DOI 10.1007/s40265-023-01930-4). Its title names Epcoritamab and its text names Diffuse large B-cell lymphoma; PubMed types it as a review (Review). It was matched automatically to the idea \"ctDNA-guided escalation and de-escalation in frontline DLBCL\" and no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Drugs 2023","url":"https://doi.org/10.1007/s40265-023-01930-4"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37597091/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/37597091"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Drugs","year":2023,"doi":"10.1007/s40265-023-01930-4","pmid":"37597091","authors":"Frampton JE","paperType":"review","findings":[],"whatItMeans":"One of the most cited reviews Europe PMC returns for Epcoritamab in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.","caveats":["Matched by Epcoritamab in the title and Diffuse large B-cell lymphoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","A review summarises other studies; the primary reports it cites are the evidence."]},"route":"/key-papers/paper-epcoritamab-dlbcl-drugs-2023/","neighbours":{"idea":[{"id":"idea-ctdna-guided-dlbcl-frontline","kind":"idea","name":"ctDNA-guided escalation and de-escalation in frontline DLBCL","route":"/ideas/idea-ctdna-guided-dlbcl-frontline/"}]}}